Inventor
FERNANDEZ-MONTALVAN AMAURY ERNESTO
DE17 patents
⚠️ This page may combine multiple inventors who share the name “FERNANDEZ-MONTALVAN AMAURY ERNESTO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
Bayer Pharma AG
7 patentsUS9765058B2Sep 19, 2017
Substituted benzylpyrazoles
Bayer Pharma AG3 citations71
US9745285B2Aug 29, 2017
Heteroaryl substituted pyrazoles
Bayer Pharma AG3 citations71
US9682974B2Jun 20, 2017
Heteroaryl substituted pyrazoles
Bayer Pharma AG4 citations71
US10350206B2Jul 16, 2019
Benzyl substituted indazoles as BUB1 inhibitors
Bayer Pharma AG1 citations61
US9890147B2Feb 13, 2018
2,3-benzodiazepines
Bayer Pharma AG2 citations59
US9663523B2May 30, 2017
BET protein-inhibiting 5-aryltriazoleazepines
Bayer Pharma AG0 citations37
US10654818B2May 19, 2020
Furane derivatives as inhibitors of ATAD2
Bayer Pharma AG0 citations36
BAYER AG
5 patentsUS11492358B1Nov 8, 2022
Macrocyclic indole derivatives
BAYER AG3 citations71
US11478451B1Oct 25, 2022
Macrocyclic chlorine substituted indole derivatives
BAYER AG3 citations71
US11447504B2Sep 20, 2022
Macrocyclic chlorine substituted indole derivatives
BAYER AG3 citations71
US11440923B2Sep 13, 2022
Substituted macrocyclic indole derivatives
BAYER AG3 citations71
US11891404B2Feb 6, 2024
Substituted macrocyclic indole derivatives
BAYER AG1 citations61
BROAD INST INC
3 patentsBAYER IP GMBH
2 patentsUS10266548B2Apr 23, 2019
Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases
BAYER IP GMBH2 citations71
US10604532B2Mar 31, 2020
Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases
BAYER IP GMBH0 citations50